ScripAmong Chinese developers of weight management medicines presenting at the June 20–23 American Diabetes Association (ADA) congress, Sciwind Biosciences and Laekna Therapeutics appeared to be the stand-
In VivoChinese companies are conducting multiple clinical trials for obesity medicines, especially domestically, and ramping up the production of semaglutide generics, meaning there’s no lack of drug options
ScripChinese companies are conducting multiple clinical trials for obesity medicines, especially domestically, and ramping up the production of semaglutide generics, meaning there’s no lack of drug options
ScripChinese biotech funding backed by venture capital and private equity firms experienced a much-needed uplift over the past few weeks, thanks partly to investor interest in assets with novel modalities